Zacks: Analysts Anticipate Pharming Group (PHGUF) Will Post Earnings of -$0.01 Per Share
Analysts expect Pharming Group (NASDAQ:PHGUF) to post earnings per share of ($0.01) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Pharming Group’s earnings, with the highest EPS estimate coming in at $0.00 and the lowest estimate coming in at ($0.01). Pharming Group also posted earnings of ($0.01) per share during the same quarter last year. The firm is scheduled to announce its next earnings report on Thursday, October 26th.
According to Zacks, analysts expect that Pharming Group will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.09) to ($0.06). For the next financial year, analysts expect that the business will report earnings of $0.01 per share, with EPS estimates ranging from ($0.01) to $0.03. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Pharming Group.
Separately, Zacks Investment Research raised shares of Pharming Group from a “sell” rating to a “hold” rating in a research report on Tuesday.
Shares of Pharming Group (PHGUF) opened at 0.53 on Friday. The stock’s market cap is $267.98 million. Pharming Group has a 1-year low of $0.17 and a 1-year high of $0.58.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/09/zacks-analysts-anticipate-pharming-group-phguf-will-post-earnings-of-0-01-per-share.html.
Pharming Group Company Profile
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.